关注我们


个人简介
2005.09--2012.06 吉林大学临床医学7年制硕士研究生
2014.08--2017.06 中山大学附属肿瘤医院肿瘤学博士研究生
2017.07--至今 广东省人民医院主治医师
研究方向
血液肿瘤的免疫治疗
代表性论著
1. Jinghua Wang#, Yanjun Wang#, Li Wan#, Xinyuan Chen, Han Zhang, Shuo Yang*, Liye Zhong*. Identification of lactate regulation pattern on tumor immune infiltration, therapy response, and DNA methylation in diffuse large B-cell lymphoma. Front Immunol, 2023, 14: p. 1230017
2. Jinghua Wang#, Siyu Chen#, Wei Xiao#, Wende Li, Liang Wang, Shuo Yang, Weida Wang, Liping Xu, Shuangye Liao, Wenjian Liu, Yang Wang, Nawei Liu, Jianeng Zhang, Xiaojun Xia, Tiebang Kang, Gong Chen, Xiuyu Cai, Han Yang, Xing Zhang*, Yue Lu*, Penghui Zhou*. CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia. J Hematol Oncol, 2018. 11(1): p. 7.
3. Jinghua Wang#, Jian Li*, Liye Zhong*. Current status and prospect of anti-amyloid fibril therapy in AL amyloidosis. Blood Rev, 2024, 66: p. 101207.
4. Zewei Zhuo#, Jinghua Wang#, Yujun Luo#, Ruijie Zeng#, Chen Zhang, Weijie Zhou, Kehang Guo, Huihuan Wu, Weihong Sha*, Hao Chen*. Targeted extracellular vesicle delivery systems employing superparamagnetic iron oxide nanoparticles. Acta Biomater, 2021, 134: p. 13-31.
5. Jinghua Wang#, Zewei Zhuo#, Yanjun Wang#, Shuo Yang#, Jierong Chen, Yulian Wang, Suxia Geng, Minming Li, Xin Du*, Peilong Lai*, Jianyu Weng*. Identification and Validation of a Prognostic Risk-Scoring Model Based on Ferroptosis-Associated Cluster in Acute Myeloid Leukemia. Front Cell Dev Biol, 2021, 9: p. 800267.
6. Yanjun Wang#, Shuo Yang#, Li Wan, Wei Ling, Hao Chen*, Jinghua Wang*. New developments in the mechanism and application of immune checkpoint inhibitors in cancer therapy (Review). Int J Oncol, 2023, 63(1).
7. Jinghua Wang#, Shuo Yang#, Pengjun Liao#, Lingji Zeng, Wei Ling, Li Wan, Jianyu Weng*, Liye Zhong*. Incidence and effect of secondary cardiac amyloidosis on outcomes of patients with t(11;14) multiple myeloma. Front Cardiovasc Med, 2022, 9: p. 994384.
8. Ruijie Zeng#, Jinghua Wang#, Zewei Zhuo, Yujun Luo, Weihong Sha*, Hao Chen*. Stem cells and exosomes: promising candidates for necrotizing enterocolitis therapy. Stem Cell Res Ther, 2021, 12(1): p. 323.
9. Wei Xiao#, Jinghua Wang#, Xizhi Wen#, Bushu Xu, Yi Que, Kuai Yu, Liping Xu, Jingjing Zhao, Qiuzhong Pan, Penghui Zhou*, Xing Zhang*. Chimeric antigen receptor-modified T-cell therapy for platelet-derived growth factor receptor α-positive rhabdomyosarcoma. Cancer, 2020, 126 Suppl 9: p. 2093-2100.
10. Ruijie Zeng#, Weihong Sha#, Jinghua Wang#, Zewei Zhuo, Huihuan Wu, Felix W Leung*, Hao Chen*. Evaluation of proton pump inhibitors and risks of gastric cancer. Gut, 2022, 71(9): p. 1924-1926.
11. Jinghua Wang#, Xinqi Qiu#, Jiayu Huang#, Zewei Zhuo#, Hao Chen, Ruijie Zeng, Huihuan Wu, Kehang Guo, Qi Yang, Huiling Ye*, Wei Huang*, Yujun Luo*. Development and validation of a novel mitophagy-related gene prognostic signature for glioblastoma multiforme. BMC Cancer, 2022, 22(1): p. 644.
12. Jinghua Wang#, Yujie Zhao#, Pengjun Liao#, Shuxin Huang, Youxue Huang, Shaohua Chen*, Yangqiu Li*, Liye Zhong*. Immune checkpoint expression patterns on T cell subsets in light-chain amyloidosis: VISTA, PD-1, and TIGIT as potential therapeutic targets. Blood Sci, 2024, 6(1): p. e00181.
13. Wei Xiao#, Liping Xu#, Jinghua Wang#, Kuai Yu#, Bushu Xu, Yi Que, Jingjing Zhao, Qiuzhong Pan, Chengqi Gao, Penghui Zhou*, Xing Zhang*. FGFR4-specific CAR-T cells with inducible caspase-9 suicide gene as an approach to treat rhabdomyosarcoma. Cancer Gene Ther, 2024, 31(10): p. 1571-1584.
14. Mengyuan Li#, Su Yao, Lingji Zeng, Jinghua Wang*. Amyloid A Amyloidosis Secondary to Thymoma. Diagnostics (Basel), 2025, 15(23).
代表性课题
1. 国家自然科学基金,2022.01-2024.12,30万元,结题,主持
2. 广东省自然科学基金,2024.01-2026.12,15万元,在研,主持
3. 国家自然科学基金,2026.01-2030.12,50万元,在研,参与
4. 广东省医学科研基金,2019.07-2021.06,0.5万元,结题,主持
5. 广州市科技计划基金,2022.04-2024.03,5万元,结题,主持
学术任职
1. 广东省精准医学应用学会精准免疫治疗分会,常委
2. 广东省精准应用学会精准血液病分会,委员
3. 广东省医学会血液病学分会青年委员会,委员
4. 广东省医学会细胞治疗学分会,委员
5. 广州抗癌协会罕见肿瘤专委会,委员
执教课程(课程及教材建设)
1. 诊断学
2. 参与编写“十三五”规划教材肿瘤学(第5版,人民卫生出版社)